Redefining Cell Therapy For Cancer
At NOK Therapeutics, we specialize in autologous Natural Killer cell therapies for cancer that are infused without lymphodepletion. This approach is designed to broaden patient access, enable convenient re-infusions, and cause deeper, longer remissions for patients.
Broad Patient Eligibility
Many patients are ineligible to receive lymphodepletion due to prior treatments or poor health. Our cells do not require lymphodepletion, increasing access to more patients.
Feasibility of Reinfusion
Without the need for lymphodepletion, multiple rounds of autologous NK cell re-infusion can be performed at more flexible, increasingly spaced intervals.
Sustained Persistence
Since our cells are autologous, they are much less likely to be rejected by the host immune system. This results in enhanced persistence and long-lasting therapeutic effects.
Preservation of the host immune system
By eliminating the need for lymphodepletion, our NK cells are able to cooperate with a fully intact host immune system, potentially sparking a comprehensive immune response.
Autologous NK Cell Therapies For Cancer
At NOK Therapeutics, our mission is to expand access to cutting-edge, life-changing cellular therapies. By eliminating the need for lymphodepletion and leveraging the intrinsic safety of NK cells, our autologous approach enables treatment after intensive therapies—such as stem cell transplants or chemotherapy. This greatly expands patient access while also potentially causing longer remissions and improved outcomes.
News and Events
Strategic Clinical Development
NOK Therapeutics is a leader in autologous NK cell therapies, targeting critical unmet needs in oncology. Our pipeline focuses on minimal residual disease (MRD)-positive situations and enhancing antibody-dependent cellular cytotoxicity (ADCC). Explore our innovative strategies and clinical development plans, below.
Useful Links
Looking to stay up to date on our latest events and news, join our team of investors, or get in touch with us directly? Follow the links below.
News & Media
Investor Hub
